| 000 | 01842 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513211120.0 | ||
| 264 | 0 | _c20000712 | |
| 008 | 200007s 0 0 eng d | ||
| 022 | _a0091-2700 | ||
| 024 | 7 |
_a10.1177/00912700022009161 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJorga, K M | |
| 245 | 0 | 0 |
_aLack of interaction between tolcapone and tolbutamide in healthy volunteers. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacology _cMay 2000 |
||
| 300 |
_a544-51 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aAryl Hydrocarbon Hydroxylases |
| 650 | 0 | 4 |
_aBenzophenones _xadverse effects |
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aCytochrome P-450 Enzyme Inhibitors |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aGlucose _xpharmacokinetics |
| 650 | 0 | 4 |
_aHeadache _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemia _xchemically induced |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xmetabolism |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNitrophenols |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 | _aSteroid 16-alpha-Hydroxylase |
| 650 | 0 | 4 |
_aSteroid Hydroxylases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTolbutamide _xblood |
| 650 | 0 | 4 | _aTolcapone |
| 700 | 1 | _aFotteler, B | |
| 700 | 1 | _aGasser, R | |
| 700 | 1 | _aBanken, L | |
| 700 | 1 | _aBirnboeck, H | |
| 773 | 0 |
_tJournal of clinical pharmacology _gvol. 40 _gno. 5 _gp. 544-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/00912700022009161 _zAvailable from publisher's website |
| 999 |
_c10758477 _d10758477 |
||